GlassScriptPhysician profile
Laura Starman
NPI 1720618457
$2,054.77
in general payments reported to CMS, 2019-2025
27 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $333 · 2023: $990 · 2024: $533 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $377.27 | 2022-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $256.59 | 2022-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $178.40 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $164.22 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $159.78 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Novartis Pharmaceuticals Corporation | $138.28 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.75 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.25 | 2022-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $63.09 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $56.06 | 2023-2024 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $47.13 | 2022-2025 | Zoryve |
| Abbvie INC. | $47.08 | 2023-2025 | |
| Astellas Pharma US INC | $46.88 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $38.34 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $31.78 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.89 | 2023-2024 | Arexvy, Shingrix |
| Sanofi Pasteur INC. | $22.71 | 2023 | |
| Pfizer INC. | $22.61 | 2024 | |
| Sanofi-Aventis U.S. LLC | $21.72 | 2022 | |
| Dexcom, INC. | $19.60 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $19.06 | 2023 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $18.10 | 2023 | Nuzyra |
| Biohaven Pharmaceutical Holding Company LTD. | $17.88 | 2022 | |
| Merck Sharp & Dohme LLC | $16.70 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $15.91 | 2024 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $13.87 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Starman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.